Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

Diabetic Gastroparesis Efficacy/Safety Study of TZP-102

ClinicalTrials.gov ID: NCT01664637

Public ClinicalTrials.gov record NCT01664637. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis

Study identification

NCT ID
NCT01664637
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Tranzyme, Inc.
Industry
Enrollment
120 participants

Conditions and interventions

Interventions

  • 10 mg TZP-102 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2012
Primary completion
Dec 31, 2012
Completion
Jan 31, 2013
Last update posted
Dec 19, 2012

2012 – 2013

United States locations

U.S. sites
23
U.S. states
14
U.S. cities
22
Facility City State ZIP Site status
Tranzyme Investigational Site Huntsville Alabama 35801
Tranzyme Investigational Site Tucson Arizona 85710
Tranzyme Investigational Site North Little Rock Arkansas 72117
Tranzyme Investigational Site Long Beach California 90822
Tranzyme Investigational Site Ventura California 93003
Tranzyme Investigational Site Hialeah Florida 33016
Tranzyme Investigational Site Inverness Florida 34452
Tranzyme Investigational Site Jacksonville Florida 32256
Tranzyme Investigational Site Miami Florida 33144
Tranzyme Investigational Site Miami Florida 33183
Tranzyme Investigational Site New Smyrna Beach Florida 32168
Tranzyme Investigational Site Anderson Indiana 46106
Tranzyme Investigational Site Indianapolis Indiana 46202
Tranzyme Investigational Site Kansas City Kansas 66160
Tranzyme Investigational Site Monroe Louisiana 71201
Tranzyme Investigational Site Boston Massachusetts 02215
Tranzyme Investigational Site Mexico Missouri 65265
Tranzyme Investigational Site Raleigh North Carolina 27612
Tranzyme Investigational Site Salisbury North Carolina 28144
Tranzyme Investigational Site Winston-Salem North Carolina 27103
Tranzyme Investigational Site Oklahoma City Oklahoma 73104
Tranzyme Investigational Site Portland Oregon 97210
Tranzyme Investigational Site El Paso Texas 79905

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01664637, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 19, 2012 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01664637 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →